October 21, 2015

Rheonix Inc. Raises $28.6 Million to Further Expand Commercialization Efforts of Molecular Diagnostic Technology

ITHACA, N.Y. — Rheonix Inc., a developer of fully automated molecular testing solutions, raised $28.6 million to further expand the company’s commercialization efforts for its breakthrough molecular testing platforms, the Encompass MDx® and Encompass Optimum™. The investment will also enable new product development and fund existing business needs. The funds are a combination of investments from existing international and domestic investors. Domestic investors include Advantage Capital Partners, Cayuga Venture Fund,… Read More »
Rheonix receives FDA Emergency Use Authorization for Automated COVID-19 Test.
Learn More